MTOR and nonpapillary renal cell carcinoma: A recent proteomic study on ccRCC by Ye’s team at Fudan University Shanghai Cancer Center revealed that the PI3K/AKT/mTOR pathway was the mechanism contributing to sunitinib resistance in ccRCC patients, which is consistent with our RNA-seq findings [9].